Uncertainty is the system, and life science marketers who build buyer presence into every decision are better equipped to navigate it.
Shownotes
Your buyer was in the room at the start of the process. By the time the brief lands in legal, they have left.
For life science product marketers, commercial leads, and anyone navigating a launch in a market that stopped following the old rules.
Matt Wilkinson and Jasmine Gruia-Gray unpack Mark Schaefer's concept of malignant uncertainty - the structural fog that makes every market assumption feel provisional. They test whether synthetic customers are a genuine solution to buyer presence erosion or a sophisticated way to lose an argument with authority. The conversation lands on a harder, more useful truth: the technology is downstream of the belief.
What you will learn:
- Why Mark Schaefer's three types of uncertainty (objective, epistemic, and subjective) reframe how life science marketers should think about the fog they are already in
- How synthetic customers make buyer insight quotable, queryable, and present through approval cycles - and why they are not a substitute for culture change
- Why the real reason buyer presence erodes in approval cycles is a prioritisation and power problem, not a data problem
- How to tell whether your synthetic customer is still accurate or has become an expensive echo chamber
- What to do practically when you are six months from a launch and the rules have structurally shifted
- What Mark Schaefer means by "leaders dispense hope" and why it is not the same as optimism
Chapters:
- [00:00] Introduction
- [00:27] Mark Schaefer and malignant uncertainty
- [01:54] The three types of uncertainty: objective, epistemic, and subjective
- [02:53] COVID, survivorship bias, and customer centricity
- [04:36] The emotional substrate beneath the surface request
- [05:24] Synthetic customers and buyer presence in approval cycles
- [06:00] Steel-manning the sceptic: is this just a sophisticated way to lose?
- [07:53] The stale data problem: synthetic customers trained on yesterday's market
- [09:23] Technology is downstream of belief
- [10:56] Practical moves six months from a launch
- [12:21] Leaders dispense hope
- [13:02] A closing exercise for listeners
-
Subscribe toA Splice of Life Science Marketing for fortnightly conversations at the intersection of commercial strategy and AI.
Read Matt's blog post on buyer presence here.